تقرير
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.
| العنوان: | Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. |
|---|---|
| المؤلفون: | Salar A; Department of Hematology, Hospital del Mar, Barcelona, Spain., Domingo-Domenech E; Department of Hematology, Hospital Durans i Reynals, Barcelona, Spain., Panizo C; Department of Hematology, Clínica Universitaria de Navarra, Pamplona, Spain., Nicolás C; Department of Hematology, Hospital Central de Asturias, Asturias, Spain., Bargay J; Department of Hematology, Hospital Son Llatzer, Mallorca, Spain., Muntañola A; Department of Hematology, Hospital Universitario Mutua de Terrassa, Terrassa, Spain., Canales M; Department of Hematology, Hospital Universitario La Paz, Madrid, Spain., Bello JL; Department of Hematology, Complejo Universitario de Santiago, Santiago de Compostela, Spain., Sancho JM; Department of Hematology, Hospital Germans Trias i Pujol, Badalona, Spain., Tomás JF; Department of Hematology, MD Anderson Cancer Center, Madrid, Spain., Rodríguez MJ; Department of Hematology, Hospital Universitario de Canarias, Tenerife, Spain., Peñalver J; Department of Hematology, Hospital Fundación Alcorcón, Alcorcón, Spain., Grande C; Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain., Sánchez-Blanco JJ; Department of Hematology, Hospital Morales Meseguer, Murcia, Spain., Palomera L; Department of Hematology, Hospital Clínico Lozano Blesa, Zaragoza, Spain., Arranz R; Department of Hematology, Hospital Universitario La Princesa, Madrid, Spain., Conde E; Department of Hematology, Hospital Marqués de Valdecilla, Santander, Spain., García M; Department of Anatomic Pathology, Hospital Universitario Miguel Servet, Zaragoza, Spain., García JF; Department of Anatomic Pathology, MD Anderson Cancer Center, Madrid, Spain; and., Caballero D; Department of Hematology, Hospital Clínico de Salamanca, Salamanca, Spain., Montalbán C; Department of Hematology, MD Anderson Cancer Center, Madrid, Spain. |
| المصدر: | Blood [Blood] 2017 Oct 12; Vol. 130 (15), pp. 1772-1774. Date of Electronic Publication: 2017 Aug 11. |
| نوع المنشور: | Clinical Trial, Phase II; Letter; Multicenter Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : [New York] : Elsevier Original Publication: New York, Grune & Stratton [etc.] |
| مواضيع طبية MeSH: | Bendamustine Hydrochloride/*therapeutic use , Lymphoma, B-Cell, Marginal Zone/*drug therapy , Rituximab/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Longitudinal Studies ; Lymphoma, B-Cell, Marginal Zone/mortality ; Male ; Middle Aged ; Prognosis ; Recurrence ; Remission Induction ; Survival Analysis |
| المشرفين على المادة: | 4F4X42SYQ6 (Rituximab) 981Y8SX18M (Bendamustine Hydrochloride) |
| تواريخ الأحداث: | Date Created: 20170813 Date Completed: 20180126 Latest Revision: 20210202 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1182/blood-2017-07-795302 |
| PMID: | 28801448 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1528-0020 |
|---|---|
| DOI: | 10.1182/blood-2017-07-795302 |